Guardant Health director exercises 4,203 RSUs

Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity.

Rhea-AI Filing Summary

Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.

Insider Trade Summary

4,203 shares exercised/converted

Exercise 3 txns

Insider Gadde Vijaya

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	4,203	$0.00	$0.00
Grant/Award	Restricted Stock Units	2,711	$0.00	$0.00
Exercise	Common Stock	4,203	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 2,711 contracts (Direct); Common Stock — 28,517 shares (Direct)

Footnotes (3)

1. F1. The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026.
2. F2. Not applicable for Restricted Stock Units.
3. F3. The restricted stock unit award vests in full on the one-year anniversary of the grant date, June 17, 2026, or the date of the Company's next annual meeting of stockholders, whichever is earlier.

Key Figures

RSUs exercised: 4,203 shares Common Stock held after transactions: 28,517 shares New RSU grant: 2,711 units +2 more

5 metrics

RSUs exercised 4,203 shares Restricted Stock Units converted to Common Stock on June 17, 2026

Common Stock held after transactions 28,517 shares Direct ownership following June 17, 2026 transactions

New RSU grant 2,711 units Restricted Stock Units granted on June 17, 2026

Exercise/award price $0.00 per unit Reported price per share for RSU exercise and grant

Vesting reference date June 17, 2026 2026 Annual Meeting of Stockholders and RSU vesting date

Key Terms

Restricted Stock Units, derivative security, Annual Meeting of Stockholders

3 terms

Restricted Stock Units financial

"The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Annual Meeting of Stockholders financial

"the 2026 Annual Meeting of Stockholders which was held on June 17, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Guardant Health (GH) director Vijaya Gadde report on June 17, 2026?

Vijaya Gadde reported exercising restricted stock units into 4,203 shares of Guardant Health Common Stock and receiving a new grant of 2,711 restricted stock units, both dated June 17, 2026, reflecting routine equity compensation activity and no open-market buying or selling.

How many Guardant Health (GH) shares does Vijaya Gadde hold after the June 17, 2026 Form 4?

After the reported transactions, Vijaya Gadde directly holds 28,517 shares of Guardant Health Common Stock. This figure reflects the net position following the June 17, 2026 restricted stock unit exercise, without any reported open-market sales or purchases in this filing.

What is the size and vesting schedule of Vijaya Gadde’s new RSU grant at Guardant Health (GH)?

The new award comprises 2,711 restricted stock units tied to Guardant Health Common Stock. The award vests in full on the earlier of June 17, 2027, the one-year anniversary of the grant date, or the company’s next annual meeting of stockholders, whichever occurs first.

Did Vijaya Gadde buy or sell Guardant Health (GH) shares on the market in this Form 4?

The Form 4 shows only equity compensation events: an exercise of 4,203 restricted stock units into Common Stock and a grant of 2,711 new restricted stock units. It does not report any open-market purchases or sales of Guardant Health shares by Vijaya Gadde.

What does the vested restricted stock unit award in June 2026 represent for Guardant Health (GH) director Vijaya Gadde?

The filing notes that a restricted stock unit award vested in full on the date of Guardant Health’s 2026 Annual Meeting of Stockholders, held June 17, 2026. That vesting corresponded to 4,203 units, which were then exercised into an equal number of Common Stock shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 05:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gadde Vijaya

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M		4,203	A	$0	28,517	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	06/17/2026		M			4,203	(1)	(2)	Common Stock	4,203	$0	0	D
Restricted Stock Units	$0	06/17/2026		A		2,711		(3)	(2)	Common Stock	2,711	$0	2,711	D

Explanation of Responses:

1. The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026.

2. Not applicable for Restricted Stock Units.

3. The restricted stock unit award vests in full on the one-year anniversary of the grant date, June 17, 2026, or the date of the Company's next annual meeting of stockholders, whichever is earlier.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Vijaya Gadde	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)